

## Special Issue

# Time for a Paradigm Shift in Non-muscle Invasive Bladder Cancer

### Message from the Guest Editor

Non-Muscle Invasive Bladder Cancer (NMIBC) is a very heterogeneous disease with a variety of treatment modalities and different follow-up regimens. Most cases of NMIBC are treated with TURBT and potential adjuvant instillation therapy, whereas the minority is treated by radical cystectomy. However, despite this variety of treatment modalities that have optimized slightly over the last few decades, a recurrence rate of more than 50% of all patients highlights the urgent need for a more optimal treatment up front. Moreover, piecemeal TURBT in NMIBC that violates normal oncological principles and life-long follow-up regimens based on traditional pathology risk stratification in a disease where biomarkers have been studied for decades calls for a change. In this Special Issue of *Cancers*, we will highlight studies where traditional approaches to NMIBC is questioned and challenged and new treatment regimens are investigated.

---

### Guest Editor

Prof. Dr. Jørgen Bjerggaard Jensen  
Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark

---

### Deadline for manuscript submissions

closed (15 May 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/88587](https://mdpi.com/si/88587)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)